title: The renal bone diseases in children treated with dialysis.
abstract: Renal osteodystrophy represents a spectrum from high- to low-turnover bone lesions. The specific pattern, however, may change during selected therapeutic interventions. As in the past, osteitis fibrosa remains the most frequent histologic lesion in pediatric patients on dialysis, although recently the prevalence of low-turnover bone lesions without aluminum toxicity has been increasing in the pediatric population. This may be a consequence of aggressive calcitriol and calcium therapy. The different factors involved in the development of secondary hyperparathyroidism include hyperphosphatemia, hypocalcemia, altered vitamin D synthesis, impairments in parathyroid hormone (PTH) secretion and metabolism, and, recently, possible downregulation of renal PTH/PTH-rP messenger RNA receptor. New developments in molecular biology have demonstrated the relationship between vitamin D and PTH. The use of high-dose pulse intravenous, intraperitoneal, and oral calcitriol therapy has significantly decreased serum PTH levels and retarded the progression of osteitis fibrosa. These therapeutic interventions, however, may have led to the development of adynamic bone lesions. The impact of adynamic bone lesions in the young and growing skeleton remains to be determined.
authors.affiliation: Department of Pediatrics, UCLA School of Medicine, CA 90095-1752, USA.
authors.forename: C P
authors.initials: CP
authors.lastname: Sanchez
authors.forename: I B
authors.initials: IB
authors.lastname: Salusky
mesh_terms: D001847:Bone Diseases / Q000209:etiology; D002117:Calcitriol / Q000627:therapeutic use; D002648:Child; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology* / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D002117:Calcitriol